NeuBase Therapeutics (NASDAQ: NBSE)

3d ago, source: The Motley Fool

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary ...

NBSE NeuBase Therapeutics, Inc.

7d ago, source: Seeking Alpha

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company ...

Why Neubase Therapeutics (NBSE) Shares Are Nosediving

on MSN ago, source:

Neubase Therapeutics Inc (NASDAQ:NBSE) shares are trading lower by 53% to $0.47 during Tuesday’s session after the company on ...

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

21d ago, source: Yahoo Finance

PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4 ...

NeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

21d ago, source: Finanznachrichten

PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company") today reported that it received a notice (the "Notice) on April 4, 2024 from ...

NeuBase Therapeutics Inc NBSE

9d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NeuBase Therapeutics Inc NBSE

15d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

NeuBase Therapeutics, Inc. Common Stock (NBSE)

22d ago, source: Nasdaq

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...

NeuBase Therapeutics Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NBSE NeuBase Therapeutics, Inc.

1mon ago, source: Seeking Alpha

The security has traded for less than one year There is no Wall Street analyst coverage The security is a closed-end fund or a mortgage REIT The security is listed on a non-US exchange The ...